ΠΡΡΡΠ°Ρ ΡΠ΅ΡΠ΄Π΅ΡΠ½Π°Ρ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΡ ΠΏΡΠΈ ΠΈΠ½ΡΠ°ΡΠΊΡΠ΅ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π°: ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-Π³Π΅ΠΌΠΎΠ΄ΠΈΠ½Π°ΠΌΠΈΡΠ΅ΡΠΊΠ°Ρ Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ° Π±ΠΎΠ»ΡΠ½ΡΡ ΠΈ ΠΎΡΠ΅Π½ΠΊΠ° ΡΡΡΠ΅ΠΊΡΠΎΠ² Π»Π΅Π²ΠΎΡΠΈΠΌΠ΅Π½Π΄Π°Π½Π° ΠΈ Π΄ΠΎΠ±ΡΡΠ°ΠΌΠΈΠ½Π°
ΠΡΠΈ ΠΏΡΠΈΠ½ΡΡΠΈΠΈ ΡΠ΅ΡΠ΅Π½ΠΈΡ ΠΎ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠΈ ΠΊΠ°ΡΠ΄ΠΈΠΎΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Π±Π΅Π· ΠΊΠ°ΡΠ΄ΠΈΠΎΠ³Π΅Π½Π½ΠΎΠ³ΠΎ ΡΠΎΠΊΠ° ΠΈ Π²ΡΠ±ΠΎΡΠ΅ ΠΊΠΎΠ½ΠΊΡΠ΅ΡΠ½ΠΎΠ³ΠΎ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΡΡΠ΅Π΄ΡΡΠ²Π° ΡΠ»Π΅Π΄ΡΠ΅Ρ ΡΡΠΈΡΡΠ²Π°ΡΡ, ΡΡΠΎ Π²ΠΎ ΠΌΠ½ΠΎΠ³ΠΈΡ ΠΏΠΎΠ΄ΠΎΠ±Π½ΡΡ ΡΠ»ΡΡΠ°ΡΡ ΠΈΠΌΠ΅ΡΡΡΡ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΡΠ΅ Π½Π°ΡΡΡΠ΅Π½ΠΈΡ Π΄ΠΈΠ°ΡΡΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΠ½ΠΊΡΠΈΠΈ Π»Π΅Π²ΠΎΠ³ΠΎ ΠΆΠ΅Π»ΡΠ΄ΠΎΡΠΊΠ°, ΠΊΠΎΡΠΎΡΡΠ΅ ΠΈΠ½ΠΎΠ³Π΄Π° Π½Π΅ ΡΠΎΠΏΡΠΎΠ²ΠΎΠΆΠ΄Π°ΡΡΡΡ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠΌ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ΠΌ Π΅Π³ΠΎ ΡΠΎΠΊΡΠ°ΡΠΈΠΌΠΎΡΡΠΈ, ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎ Π² ΡΠ°Π½Π½ΠΈΠ΅ ΡΡΠΎΠΊΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ. ΠΡΠ΅Π²ΠΈΠ΄Π½ΠΎ, ΠΏΡΠΈ ΠΈΠ·ΠΎΠ»ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ… Π§ΠΈΡΠ°ΡΡ Π΅ΡΡ >
Π‘ΠΏΠΈΡΠΎΠΊ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ
- Eldrin F. Lewis, Eric J., et al. Predictors of the First Heart Failure Hospitalization in Patients Who Are Stable Survivors of Myocardial Infarction Complicated By Pulmonary Congestion and/or Left Ventricular Dysfunction. Eur Heart J 2008- 29:748−756.
- Abbas S., Benjamin A., Ryblcki A., et al. Clinical Predictors of Heart Failure in Patients With First Acute Myocardial Infarction. Am Heart J 1999- 138: 1133−1139.
- Rosamond W., Flegal K., Friday G., et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007- 115: e69−171.
- Guidelines on the diagnosis and treatment of acute heart failure. The Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005- 26: 384−416.
- Lim N. et al. Do All Nonsurvivors of Cardiogenic Shock Die With a Low Cardiac Index? Chest 2003- 124: 1885−1891.
- Adams K.F., Fonarow G.C., Emerman C.L., et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute
- Decompensated, Heart Failure National5 Registry (ADHERE). Am Heart X 2005- 149: 209−216.
- Nieminenl M.S., Brutsaert D., Dickstein K., et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 2006- 27: 2725−2736.
- Π―Π²Π΅Π»ΠΎΠ² Π.Π‘. ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠ°Ρ/ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΡΠ΅Π½ΡΠΈΡΠΈΠ·Π°ΡΠΎΡΠ° ΠΊΠ°Π»ΡΡΠΈΡ* — ΠΏΡΠ΅Π΄ΡΡΠ°Π²ΠΈΡΠ΅Π»Ρ Π½ΠΎΠ²ΠΎΠ³ΠΎ^ ΠΊΠ»Π°ΡΡΠ° ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² Ρ ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½ΡΠΌ ΠΈΠ½ΠΎΡΡΠΎΠΏΠ½ΡΠΌ Π΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ΠΌ ΠΏΡΠΈ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΠΈ ΠΈ ΠΈΠ½ΡΠ°ΡΠΊΡΠ΅ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π°. Π‘Π΅ΡΠ΄Π΅ΡΠ½Π°Ρ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΡ 2005- ΡΠΎΠΌ 6, № 1: 33−45
- FollatbF., Gleland J.G., Just H., et Π°Π. Efficacy and* safety of intravenous-levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002- 360: 196−202.
- CASINO-results: — Should’docs gamble on- levosimendan? Π‘ΠΎΠΎΠ±ΡΠ΅Π½ΠΈΠ΅ ΠΏΠΎΠ΄Π³ΠΎΡΠΎΠ²ΠΈΠ» Nainggolan L. www.theHeart.org1
- REVTVE-2: Levosimendan improves five-day clinical"status in acute HF. Π‘ΠΎΠΎΠ±ΡΠ΅Π½ΠΈΠ΅ ΠΏΠΎΠ΄Π³ΠΎΡΠΎΠ²ΠΈΠ» Stiles S. www.theHeart.org
- Mebazaa Al, Nieminen MiS., Packer Ml, et al. Levosimendan vs Dobutamine for Patients With1 Acute, Decompensated, Heart Failure. The* SURVIVE Randomized Trial. JAMA. 2007- 297: 1883−1891.
- Killip4 Π’., Kimball J.T. Treatment of myocardial infarction4n a coronary care unit: a two year experience with 250 patients. Am J Cardiol 1967- 20: 457 464.
- Goldberg RJ, Gore JM, Alpert JS, et al. Cardiogenic shock after acute myocardial infarction: incidence and, mortality from' a community-wide perspective, 1975 to 1988. N Engl J Med 1991- 325: 1117−1122
- Holmes- DIR. Jr., Bates E.R., Kleiman N.S. et al. Contemporary reperfusiom therapy for- cardiogenic shock: the GUSTO-I trial experience. JACC 1995- 26: 668−674.
- Menon V., Hochman J. S., Stebbins A., et al: Lack of progress in cardiogenic shock: lessons from theGUSTOtrials: Eur, HeartvJ 2000- 21> 19 281 936. — β’ ' 'Β¦. Β¦. ' - «. — :
- Π―Π²Π΅Π»ΠΎΠ² Π.Π., ΠΡΠ°ΡΠΈΠ°Π½ΡΠΊΠΈΠΉ H.A. Π ΠΎΡΡΠΈΠΉΡΠΊΠΈΠΉ ΡΠ΅Π³ΠΈΡΡΡ ΠΎΡΡΡΡΡ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΡΡ ΡΠΈΠ½Π΄ΡΠΎΠΌΠΎΠ²: Π»Π΅ΡΠ΅Π½ΠΈΠ΅ ΠΈ ΠΈΡΡ ΠΎΠ΄Ρ Π² ΡΡΠ°ΡΠΈΠΎΠ½Π°ΡΠ΅ ΠΏΡΠΈ ΠΎΡΡΡΠΎΠΌ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΠΎΠΌ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ΅ Π±Π΅Π· ΠΏΠΎΠ΄ΡΠ΅ΠΌΠΎΠ² ΡΠ΅Π³ΠΌΠ΅Π½ΡΠΎΠ² ST. ΠΠ°ΡΠ΄ΠΈΠΎΠ»ΠΎΠ³ΠΈΡ 2003- 43 (12): 16−29. '. «. *
- Π―Π²Π΅Π»ΠΎΠ² Π.Π‘., ΠΡΠ°ΡΠΈΠ°Π½ΡΠΊΠΈΠΉ Π. Π. Π ΠΎΡΡΠΈΠΉΡΠΊΠΈΠΉ ΡΠ΅Π³ΠΈΡΡΡ ΠΎΡΡΡΡΡ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΡΡ ΡΠΈΠ½Π΄ΡΠΎΠΌΠΎΠ²: Π»Π΅ΡΠ΅Π½ΠΈΠ΅ ΠΈ ΠΈΡΡ ΠΎΠ΄Ρ Π² ΡΡΠ°ΡΠΈΠΎΠ½Π°ΡΠ΅ ΠΏΡΠΈ ΠΎΡΡΡΠΎΠΌ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΠΎΠΌ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ΅ Ρ ΠΏΠΎΠ΄ΡΠ΅ΠΌΠ°ΠΌΠΈ ΡΠ΅Π³ΠΌΠ΅Π½ΡΠ°- ST. ΠΠ°ΡΠ΄ΠΈΠΎΠ»ΠΎΠ³ΠΈΡ: 2004, № 4: 413. Β¦ ': —. Β¦ / .' Β¦ - β’ ,
- Webb J.G., Sleeper Πͺ. A., Buller Π‘.Π., et al. Implications of the Timing of Onset of Cardiogenic Shock After Acute Myocardial Infarction: A Report from"the SHOCK Trial Registry. JACC 2000- 36: 1084−1090:
- Bhatia R.S., Tu J.V., Lee D.S., et al. Outcome of Heart Failure: with Preserved- Ejection Fraction- in a Population-Based Study. N Engl? J Med- 2006- 355:260−269.
- Eichoru E.I. Are contraction and: relaxation coupled in patients with and without congestive heart failure? Eur Heart J 1992- 3: 39−43.
- Devereux R.B. Detection of left ventricular hypertrophy by M-mode echocardiography. Anatomic validation^ standartization and comparison to other methods. Hypertension, 1987- 9 (Suppl. II): 19−26.
- Nishimura R.A., Tajik A.J. Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is. the clinician’s Rosetta stone // JACC 1997- 30: 8−18.
- Benjamin E. J, Levy D., Anderson K.M., et al. Determinants of Doppler indexes of left ventricular diastolic- function in normal subjects (the Framingham Heart Study). Am J Cardiol 1992- 70: 508−515.
- Kannel W.B. Left ventricular hypertrophy as a risk factor, in arterial hypertension. Eur Heart J 1996- 13 (Suppl D): 82−88. /
- Richards A.M., Nicholls M.G., Yandle T.G., et al. Neuroendocrine prediction of. left ventricular function and heart failure after acute myocardial infarction. Heart 1999- 81:114−120.
- Poulsen S.H., Jensen S.E., Egstrup K. Longitudinal changes and prognostic implications of LV diastolic function in first acute myocardial, infarction. Am Heart J 1999- 137: 910−918.
- Conti C.R. Determining prognosis early after a myocardial infarction. Eur HeartJ 2000- 21: 609−610.
- GUSTO investigators. The effects of tissue plasminogen activator, streptokinase or both on coronary artery potency, ventricular function and servival after acute myocardial infarction. N Engl J Med 1993- 329: 1615−1622.
- White H.D. Remodelling of the heart after myocardial infection. Australian and New Zealand J of Medicine 1992- 22: 601−606.
- Pipilis A., Meyer Π’.Π., Ormerod O., et al. Early and late changes in left ventricular filling after acute myocardial infarction and the effect of infarct size. Am J Cardiol 1992- 70: 1397−1401.
- Poulsen- S.H., Jensen S.E., Egstrup K. Longitudinal changes and prognostic implications of LV diastolic function in first acute myocardial infarction. Am Heart J 1999- 137: 910−918.
- ΠΠΈΠΊΠΈΡΠΈΠ½ Π.Π., ΠΠΆΠΎΠ½ ΠΠΆ. Π€. ΠΠ»ΠΈΠ»Π°Π½Π΄. ΠΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΡΠΊΠ°Π½Π΅Π²ΠΎΠΉ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄ΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π΄ΠΎΠΏΠΏΠ»Π΅ΡΡΡ ΠΎΠΊΠ°ΡΠ΄ΠΈΠΎΠ³ΡΠ°ΡΠΈΠΈ Π² ΠΊΠ°ΡΠ΄ΠΈΠΎΠ»ΠΎΠ³ΠΈΠΈ. ΠΠ°ΡΠ΄ΠΈΠΎΠ»ΠΎΠ³ΠΈΡ 2002- № 3: 66−79.
- Garcia M.J., Thomas J.D., Klein A.L. New Doppler echocardiographic applications for the study of diastolic function. JACC 1998 32: 865−875.
- Kucherer H.F., Kuebler W.W. Diagnosis of left ventricular hypertrophy by echocardiography. J Cardiovasc Pharmacol 1992- 19: S81-S86.
- Galderisi M., Mele D., Marino P. Qantitation of stress echocardiography by tissue Duppler and strain rate imaging: a dream come true? Ital Heart J 2005: 6: 9−20.
- Ommen S.R., Nishimura RA. A clinical approach to the assessment of left ventricular diastolic function by Doppler echocardiography: update 2003. Heart 2003- 89 (suppl. Ill): III18- Π123.
- Pium H.P., Beyerbacht J.C., Chinf A., et al. Comparison of echocardiography with magnetic resonance imaging in the assessment of the athlete’s heart. Eur Heart J 1997- 18: 223−227.
- Garcia M.J., Thomas J.D., Klein A.L. New Doppler echocardiography applications for the study of diastolic function. JACC 1998- 32: 865−875.
- Yamamoto K., Redfield M.M., Nishimura R.A. Analysis of left ventricular diastolic function. Heart 1996- 75: 27−35.
- ΠΠ²Π°Π½ΠΎΠ² Π. Π., ΠΡΠ°ΡΠ΅Π² C.B., Π‘ΡΡΠΊΠΈΠ½ A.JI. ΠΠ»Π΅ΠΊΡΡΠΎΠΊΠ°ΡΠ΄ΠΈΠΎΠ³ΡΠ°ΡΠΈΡ Π²ΡΡΠΎΠΊΠΎΠ³ΠΎ ΡΠ°Π·ΡΠ΅ΡΠ΅Π½ΠΈΡ Π. «Π’ΡΠΈΠ°Π΄Π°-Π₯», 2003.
- Geil S., Nowak Π., Liebrich A., et al. Late potentials in the diagnosis of post-infarction patients: arrhythmogenic risk and clinical symptomatology. Z Kardiol 1997- 86: 883−890.
- Steinbigler P., Haberl R., Π^Π΅ G., et al. Analysis of functional changes in ventricular late potentials for risk assessment of ventricular tachycardias after myocardial infarct. Z Kardiol 1998- 87: 459−470.
- Ikeda Π’., Sakata Π’., Takami M., et al. Combined assessment of T-wave alternans and late potentials used to predict arrhythmic events after myocardial infarction. A prospective study. JACC 2000- 35: 722−730.
- Steinbigler P., Haberl R., Bruggemann Π’., et al. Postinfarction risk assessment for sudden cardiac death using late potential analysis of the digital Holter electrocardiogram. J Cardiovasc Electrophysiol 2002- 13: 1227−1232.
- Swiatowiec A., Dluzniewski M., Mamcarz A., Kuch M. Effect of thrombolytic therapy on the prevalence of ventricular late potentials in patients after myocardial infraction. Pol Arch Med Wewn 2003- 110: 1423−1429.
- Steinbigler P., Haberl R., Jilge G., Steinbeck G. Circadian variability of late potential analysis in Holter electrocardiograms. Pacing Clin Electrophysiol 1999- 22:1448−1456.
- Steinbigler P., Haberl R., Hoffmann E., Steinbeck G. Variable late potentials in long-term ECG of the post-infarct patient at risk for ventricular fibrillation. Z Kardiol 2000- 89: 274−283.
- Steinbigler P., Haberl R., Jilge G., et al. Analysis of functional changes in ventricular late potentials for risk assessment of ventricular tachycardias after myocardial infarct. Z Kardiol 1998- 87: 459−470.
- Steinbigler P., Haberl R., Jilge G., Steinbeck G. Circadian variability of late potential analysis in Holter electrocardiograms Pacing Clin Electrophysiol 1999- 22: 1448−1456.
- Iltumur K., Karabulut A., Temamogullari A.V., et al. The relation between infarction localization and late potentials. Anadolu Kardiyol Derg 2001- 1:76−79.
- Malik M., Batchvarov V.N. Measurement, Interpretation and Clinical Potential of QT Dispersion. JACC 2000- 36: 1749−1766.
- Paventi S., Bevilacqua U., Parafati M.A., et ah QT dispersion and early arrhythmic risk during acute myocardial infarction. Angiology 1999- 50: 209−215.
- Ciolli A., Di Lorenzo M., Bevilacqua U., et al. QT dispersion and early arrhythmic risk during acute myocardial infarction. G Ital Cardiol 1999- 29: 14 381 444.
- Jain H., Avasthi R. Correlation between dispersion of repolarization (QT dispersion) and ventricular ectopic beat frequency in patients with acute myocardial infarction: a marker for risk of arrhythmogenesis? Int J Cardiol 2004- 93: 69−73.
- Enar R., Pehlivano S., Uzunhasan I., et al. The Relation Between Early Ventricular Tachycardia and QT Dispersion in Patients with Acute Myocardial Infarction Treated with Thrombolytic Therapy. Int J Angiol 2001- 10: 58−62.
- Dabrowski A., Kramarz E., Piotrowicz R., Kubik L. Predictive power of increased QT dispersion in ventricular extrasystoles and in sinus beats for risk stratification after myocardial infarction. Circulation 2000- 101: 1693−1697.
- Parale G.P., Adnaik A.R., Kulkarni P.M. Dynamics of QT dispersion in acute myocardial infarction. Indian Heart J 2003- 55: 628−623.
- Ciolli A., Di Lorenzo M., Bevilacqua U., et al. QT dispersion and early arrhythmic risk during, acute myocardial infarction- G Ital Cardiol 1999- 29: 1438' 1444.
- ΠΠΎΠΈΡΠ΅Π΅Π² B.C. ΠΡΡΡΠ°Ρ ΡΠ΅ΡΠ΄Π΅ΡΠ½Π°Ρ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΡ. ΠΠΎΠ²ΡΠ΅ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ Ρ: ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ΠΌ ΡΠ΅Π½ΡΠΈΡΠΈΠ·Π°ΡΠΎΡΠ° ΠΊΠ°Π»ΡΡΠΈΡ Π»Π΅Π²ΠΎΡΠΈΠΌΠ΅Π½Π΄Π°Π½Π°. Π€Π°ΡΠΌΠ° ΠΡΠ΅ΡΡ, 2004.. :
- Cotter G., Moshkovitz Y., Milovanov O. et al. Acute heart failure: a novel approach to its pathogenesis and treatment. Eur J Heart Fail 2002- 4: 227−234.
- Holmes C.L., Walley K.R. Low-Dose Dopamine in the ICU. Chest 2003-:, 123: 1266−1275.
- Stevenson L.W. Clinical Use of Inotropic Therapy for Heart Failure: Looking Backward or Forward? Part I: Inotropic Infusions During Hospitalization. Circulation 2003- 108: 367−372.
- Cuffe M.S., Califf R.M., Adams K.F. Jr. et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial: JAMA 2002- 287: 1541−1547.
- Lochner A., Colesky F., Genade S. Effect of a calcium-sensitizing agent, levosimendan, on the postcardioplegic inotropic response of the myocardium. Cardiovasc Drugs Ther 2000- 14: 271−281.
- Janssen P.M.L., Datz N., Zeitz O. et al. Levosimendan improves diastolic and systolic function in failing human myocardium. Eur J Pharmacol' 2000- 404: 191−199.
- Haikala H., Nissinen E., Etemadzadeh E. et al. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol 1995- 25: 794−801.
- Hasenfuss G., Pieske Π., Castell M. et al. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation 1998- 98: 2141−2147.
- Kaheinen P., Pollesello P., Levijoki J., Haikala H. Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. J Cardiovasc Pharmacol 2001- 37: 367−374.
- Haikala H., Kaheinen P., Levijoki J., Linden I-B. The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan. Cardiovasc Res 1997- 34: 536−546.
- Szilagyi S., Pollesello P., Levijoki J. et al. The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. Eur J Pharmacol 2004- 486: 67−74.
- Lancaster M.K., Cook S J. the effects of Ca2+.j in guinea-pig isolated ventricular myocytes. Eur J Pharmacol 1997- 339: 97−100.
- Kaheinen P., Pollesello P., Levijoki J., Haikala H. Effects of levosimendan and milrinone on oxygen consumption in isolated guinea-pig heart. J Cardiovas Pharmacol 2004- 43: 555−561.
- Sundberg S., Lilleberg J., Nieminen M.S. et al. Hemodynamic and neurohumoral effects of levosimendan, a new calcium sensitizer, at rest and during exercise in healthy men. Am J Cardiol 1995- 75: 1061−1066.
- Lilleberg J., Sundberg S., Hiiyhii M. et al. Haemodynamic dose efficacy of levosimendan in healthy volunteers. Eur J Clin Pharmacol 1994- 47: 267−274.
- Lilleberg J., Sundberg S., Nieminen M.S. Dose-range study of a new calcium sensitizer, levosimendan, in patients with left ventricular dysfunction. J Cardiovasc Pharmacol 1995- 26 Suppl. 1: 63−69.
- Nieminen M., Akkila J., Hasenfuss G. et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. JACC 2000- 36: 1903−1912.
- Slawsky M.T., Colucci W.S., Gottlieb S.S. et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Curculation 2000- 102: 2222−2227.
- Sonntag S., Sundberg S., Lehtonen L.A., Kleber F.X. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. JACC 2004- 43: 2177−2182.
- Lilleberg J., Nieminen M.S., Akkila J. et al. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 1998- 19: 660−668.
- Nijhawan N.*, Nicolosi’A.C., Montgomery M.W. et al. Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial. J Cardiovasc Pharmacol 1999- 34: 219−228.
- Michaels A.D., McKeown Π., Kostal M., et al. Effects of Intravenous Levosimendan on Human Coronary Vasomotor Regulation, Left Ventricular Wall Stress, and Myocardial Oxygen Uptake. Circulation 2005- 111: 1504−1509.
- Parrisis J.T., Filippatos G., Farmakis D., et al. Levosimendan for the treatment of acute heart failure syndromes. Expert Open Pharmacother 2005- 6: 2741−2751.
- Papp Z., Csapo K.,< Pollesello P., et al. Pharmacological Mechanisms ' Contributing to the Clinical Efficacy of Levosimendan. Cardiovasc Drugs Rev 2005- 23: 87−114.
- Haikala H.», Levijoki J., Linden I-B. Effect of levosimendan via troponin Π‘ is controlled by intracellular calcium load and calcium influx. J Mol Cell Cardiol 1995- 27: A109.
- Varro A., Papp J.G. Classification of positive inotropic actions based on electrophysiologic characteristics: where should calcium sensitizers be placed? J Cardiovasc Pharmacol 1995- 26 (Suppl. 1): 32−44.f
- Hasenfuss G., Holubarsch H., Blanchard E. et al. Energetic aspects of inotropic interventions in rat myocardium. Basic Res Cardiol 1987- 82: 251−259:
- Haikala H., Kaheinen P., Levijoki J., Linden I-B. The role of cAMP-and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan. Cardiovasc Res 1997- 34: 536−546.
- Kaheinen P, Pollesello P., Levijoki J., Haikala H. Effects of levosimendan and milrinone on oxygen consumption-in isolated guinea-pig heart. J Cardiovasc Pharmacol-2004- 43: 555−561.
- Yokoshiki H, Katsube Y., Sunagawa M, Sperelakis N. The novel calcium sensitizer levosimendan activates the ATPsensitive K+ channel in rat ventricular cells. J Pharmacol Expt’Ther 1997- 283: 375−383.
- Bowman P., Haikala H., Paul R.J. Levosimendan-, a calcium sensitizer in' cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization. J Pharmacol Exp Ther 1999- 288: 316−325.
- Pataricza J., Holm J., Petri A. et al. Comparison of the vasorelaxing effect of cromakalim- and the new inodilator, levosimendan, in human isolated portal vein. JPharm Pharmacol2000- 52: 213−217.
- Ukkonen HI, Saraste M., Akkila J. et al. Myocardial efficiency during levosimendan infusion in congestive heart failure. Clinical Pharmacology and Therapeutics 2000- 68: 522−531.
- Pataricza J., Hohn J., Petri A. et al. Comparison' of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein. J Pharm Pharmacol 1997- 52: 213−217.
- Ukkonen H., Saraste M., Akkila J. et al. Myocardial efficiency during calcium sensitization with levosimendan: a noninvasive study with positron emission tomography and echocardiography in healthy volunteers. J Clin Pharmacol Ther 1997- 61: 596−607.
- Yokoshiki H., Katsube Y., Sunagawa M., Sperelakis N. The novel calcium sensitizer levosimendan activates the ATPsensitive K+ channel in rat ventricular cells. J Pharmacol Expt Ther 1997- 283: 375−383.
- Follath F., Cleland J.G., Just H., et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002- 360: 196−202.
- Kivikko M., Lehtonen L., Colucci W.S., on Behalf of Study Investigators. Sustained hemodynamic affects of intravenous levosimendan. Circulation 2003- 107: 81−86.
- Yokoshiki H., Katsube Y., Sunagawa M. et al. Levosimendan, a novel24* «f*
- Ca sensitizer, activates the glibenclamide-sensitive Π channel* in rat arterial myocytes. Eur J Pharmacol 1997- 333: 249−259.
- Kaheinen P., Haikala H. Increases in diastolic coronary flow by levosimendan and pinacidil are differently mediated through opening of the ATP-sensitive potassium channels. JACC1998- 31 (Suppl. Π‘): 154C.
- Gruhn N., Nielsen-Kudsk J.E., Theilgaard S. et al. Coronary vasorelaxant effect of levosimendan, a new inodilator with calcium-sensitizing properties. J Cardiovasc Pharmacol 1998- 31: 741−749.
- Kersten J.R., Montgomery M.W., Pagel P. S., Warltier D.C. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of KATP channels. Anesth Analg 2000- 90: 5−11.
- Kopustinskiene D., Pollesello P., Saris N.E. Potassium-specific effects of levosimendan on heart mitochondria. Biochem Pharmacol 2004- 68: 807−812.
- Hohn J., Pataricza J., Petri A. et al. Levosimendan interacts with potassium channel blockers in human saphenous veins. Basic Clin Pharmacol Toxicol 2004- 94: 271−273.
- Kopustinskiene D., Pollesello P., Saris N.E. Levosimendan is a mitochondrial Katp channel opener. Eur J Pharmacol 2001- 428: 311−314.
- Jamali I.N., Kersten J.R., Pagel P. S., Hettrick D.A., Warltier D.C. Intracoronary levosimendan enhances contractile function of stunned myocardium. Anesth Analg 1997- 85: 23−29.
- Nicklas J.M., Monsur J.C., Bleske B.E. Effects of intravenous levosimendan on plasma neurohormone levels, in patients with heart failure: relation to hemodynamic response. Am J Cardiol 1999- 83: 12(1)-15(1).
- Binkley P.F., Nunziata E., Hatton P. S., Leier C.V. The positive inotropic agent levosimendan mediates increased cardiac output without progression of sympathovagal, imbalance in patients with heart failure. Circulation 2000- 18 (suppl): 102.
- Barakal K., Wilkinson P., Deaner A., et al. How should age affect management of acute myocardial infarction? A prospective cohort study. Lancet 1999- 353: 955−959.
- Kober L., Pedersen G.T. Clinical characteristics and mortality of patients screend for entryinto Trandolapril Cardiac Evaluation, (TRACE) study. Am J Cardiol 1995- 76: 1−5.
- Poulsen S.H. Clinical aspects of left ventricular diastolic function assessed by Doppler echocardiography following acute myocardial infarction. Dan Med Bull 2001- 48: 199−210.
- Poulsen S.H., Moller J.E., Norager Π., Egstrup K. Prognostic implications of left ventricular diastolic dysfunction with preserved systolic function following acute myocardial infarction. Cardiology 2001- 95: 190−197.
- Garcia-Rubira J.C., Garcia-Martinez J.T., Hidalgo R., et al. Doppler transmittal flow pattern is an independent prognostic factor in acute myocardial infarction. Cardiology 1997- 88:203−206.
- Π§Π°Π·ΠΎΠ² Π.Π., Π ΡΠ΄Π° Π. Π―. Π’ΡΠΎΠΌΠ±ΠΎΠ»ΠΈΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΠ΅ΡΠ°ΠΏΠΈΡ, ΠΏΡΠΈ ΠΈΠ½ΡΠ°ΡΠΊΡΠ΅ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π°. ΠΠ°ΡΠ΄ΠΈΠΎΠ»ΠΎΠ³ΠΈΡ 1987- № 2: 5−12.
- Boggs W. Carvedilol Reduces Mortality Risk Soon After MI With LV Dysfunction. Am Heart J 2007- 154: 637−644.
- Ambrosioni E., Borghi C., Magnani B. The effect of the angiotensin converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995- 332: 80−119.
- Hollenberg S., el al. Cardiogenic shock. Ann Intern Med 1999- 131: 4759.
- Lehtonen L., el al. Pharmacokinetics and pharmacodynamics of intravenous inotropic agents. Clin Pharmacokinet 2004- 43: 187−203.
- Π¨Π»ΡΡ ΡΠΎ E.B. ΠΈ ΡΠΎΠ°Π²Ρ. ΠΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΡΠΊΠ°Π½Π΅Π²ΠΎΠΉ Π΄ΠΎΠΏΠΏΠ»Π΅ΡΠΎΠ³ΡΠ°ΡΠΈΠΈ Π΄Π»Ρ ΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΎΠΉ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΠΎΠ³ΠΎ ΡΡΡΠ»Π° Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΠΠ‘. Π£Π»ΡΡΡΠ°Π·Π²ΡΠΊΠΎΠ²Π°Ρ ΠΈ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½Π°Ρ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ° 2004- № 3: 113−115.
- Stevenson L. Clinical use of inotropic therapy for heart failure: looking backward or forward? Part 1: inotropic infusions during hospitalization. Circulation 2003- 108: 367−372.
- Bauer A., Guzik P., Barthel P., et al. Reduced prognostic power of ventricular late potentials in post-infarction patients of the reperfiision era. Eur Heart J 2005- 26: 755−761.
- ΠΠ²Π°Π½ΠΎΠ² Π. Π., ΠΡΠ°ΡΠ΅Π² C.B., Π‘ΡΡΠΊΠΈΠ½ A.JI. ΠΠ»Π΅ΠΊΡΡΠΎΠΊΠ°ΡΠ΄ΠΈΠΎΠ³ΡΠ°ΡΠΈΡ Π²ΡΡΠΎΠΊΠΎΠ³ΠΎ ΡΠ°Π·ΡΠ΅ΡΠ΅Π½ΠΈΡ. Π., Π’ΡΠΈΠ°Π΄Π°-Π₯, 2003.
- Malik Π., Balchvarov V. Measurement, interpretation and clinical potential of QT dispersion. JACC 2000- 36: 1749−1766.